BUSINESS● LOWSep 8 · Sep 8, 2026, 2:26 PM
Amgen drops on Novartis trial setback for heart therapy; BMO downgrades
Seeking Alpha Tech · global
Amgen's stock has fallen due to a trial setback for Novartis's heart therapy and a subsequent downgrade by BMO. This illustrates how news from a competitor can impact a company's market valuation.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Business
BUSINESSnowMunicipal Securities Underwriters Pay a Total of $325,000 in FinesSECBUSINESSnowSEC CHAIRMAN ARTHUR LEVITT, IOWA OFFICIALS TO HOLD INVESTORS’ TOWN MEETING IN DES MOINESSECBUSINESS4m agoEaton Non-GAAP EPS of $3.68 beats by $0.13, revenue of $8.95B beats by $420MSeeking Alpha TechBUSINESS5m agoShares in Russian social media company VK rise 45% over just a few daysMeduza [en]